HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver

This article was originally published in The Rose Sheet

Executive Summary

Fourth quarter and fiscal year 2004 sales and earnings are expected to meet or exceed Wall Street estimates, firm says Sept. 22. Results are bolstered by Alberto's strategy of "advertising at record levels behind solid Alberto VO5, St. Ives and TRESemme product propositions, and by focusing on fewer and bigger brands, geographies and customers," according to CEO Howard Bernick. Alberto VO5, St. Ives, and TRESemme are all "more profitable today than ever before, and are better positioned than ever to continue to thrive in 2005 and future years here in the U.S. and overseas," exec adds...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel